Summary
This document is a guide detailing the innovative EVERSANA Direct model, which combines Direct-to-Patient and Direct-to-Payer approaches to enhance market access in the pharmaceutical industry. It outlines the challenges faced by the healthcare ecosystem, including rising costs and fragmented care, and emphasizes the need for new strategies rather than merely fixing existing processes. The guide explains how the merger of EVERSANA and Waltz Health aims to create a more transparent and reliable system for therapy delivery. It describes how the model empowers payers by providing upfront pricing, which facilitates better budgeting and eliminates unpredictable rebate structures. Additionally, the guide highlights the benefits for pharmaceutical manufacturers, including increased access to therapies and improved financial health through streamlined processes. The document emphasizes the importance of aligning incentives among stakeholders to improve patient outcomes and ensure a seamless experience throughout the prescription journey.
